Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums

Health Affairs

Volumn 33, Issue 10, 2014, Pages 1761-1769

  Starner, Catherine I ^a   Alexander, G Caleb ^b   Bowen, Kevin ^a   Qiu, Yang ^a   Wickersham, Peter J ^a   Gleason, Patrick P ^a  

^a Prime Therapeutics LLC   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG; SPECIALTY DRUG; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; DRUG COUPON; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRESCRIPTION; COST; COST CONTROL; ECONOMICS; HEALTH CARE COST; HEALTH CARE POLICY; INSURANCE; MEDICATION COMPLIANCE; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANTI-INFLAMMATORY AGENTS; COST SAVINGS; COST SHARING; DRUG COSTS; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; PRESCRIPTION DRUGS;

EID: 84907853401     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0497     Document Type: Article

References (29)

1. Prime Therapeutics. Analysis of more than ten million privately insured patients with combined medical and pharmacy claims data. Eagan (MN): Prime Therapeutics LLC. Unpublished data.
2. Prime Therapeutics. 2012 drug trend insights [Internet]. Eagan (MN): Prime Therapeutics; [cited 2014 Aug 14]. Available from: http://www.primetherapeutics.com/pdf/2012PrimeDrugTrendInsights.pdf
3. IMS Institute for Healthcare Informatics. Healthcare spending among privately insured individuals under age 65 [Internet]. Parsippany (NJ): IMS; 2012 Feb [cited 2014 Aug 14]. Available from: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20 Institute%20for%20Healthcare %20Informatics/Healthcare%20Spending/IHII_Spending_Report.pdf
4. Express Scripts. 2013 drug trend report [Internet]. Washington (DC): Express Scripts; 2014 Apr [cited 2014 Aug 14]. Available from: http://lab.express-scripts.com/~/media/pdfs/drug%20trend%20report/express%20scripts%202013%20 drug%20trend%20report.ashx
5. Herper M. How a $440,000 drug is turning Alexion into biotech's new innovation powerhouse. Forbes [serial on the Internet]. 2012 Sep 5 [cited 2014 Aug 14]. Available from: http://www.forbes.com/sites/matthewherper/2012/09/05/how-a-440000-drug-is-turning-alexioninto-biotechs-new-innovation-powerhouse/2/
6. Jacobs MS, Johnson KA. Curbing the costly trend: exploring the need for a progressive approach to the management of specialty pharmaceuticals under the medical benefit. Am Health Drug Benefits. 2012;5(5): 280-9.
7. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319-31.
8. Tu HT, Samuel DR. Limited options to manage specialty drug spending [Internet]. Washington (DC): Center for Studying Health System Change; 2012 Apr [cited 2014 Aug 14]. (Research Brief No. 22). Available from: http://www.hschange.com/CONTENT/1286/
9. Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, et al. Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm. 2013;19(7): 542-8.
10. Baldini CG, Culley EJ. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a Medical Injectable Drug program. J Manag Care Pharm. 2011;17(1):51-9.
11. Motheral BR. Pharmaceutical steptherapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143-55.
12. Navarro JP, Johnson KA. Opportunities and challenges of specialty pharmaceuticals. J Manag Care Pharm. 2013;19(1):70-1.
13. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8): 648-58.
14. Karaca-Mandic P, Joyce GF, Goldman DP, Laouri M. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Serv Res. 2010;45(5 Pt 1):1227-50.
15. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 2008;59(10): 1519-26.
16. Palmer L, Abouzaid S, Shi N, Fowler R, Lenhart G, Dastani H, et al. Impact of patient cost sharing on multiple sclerosis treatment. Am J Pharm Benefits. 2012;4(special issue): SP28-36.
17. Fein AJ. Co-pay offset programs are blooming in specialty pharmacy. Drug Channels [blog on the Internet]. 2014 Mar 19 [cited 2014 Aug 14]. Available from: http://www.drugchannels.net/2014/03/co-payoffset-programs-are-blooming-in.html
18. Ross JS, Kesselheim AS. Prescription-drug coupons-no such thing as a free lunch. N Engl J Med. 2013; 369(13):1188-9.
19. Pharmacy Benefit Management Institute. 2014 PBMI specialty drug benefit report. Plano (TX): PBMI; 2014.
20. Kaiser Family Foundation, Health Research and Educational Trust. 2013 employer health benefits survey [Internet]. Menlo Park (CA): KFF; 2013 Aug 20 [cited 2014 Aug 14]. Available from: http://kff.org/private-insurance/report/2013-employer-health-benefits
21. American Pharmacists Association. Specialty pharmacy: a unique and growing industry [Internet]. Washington (DC): The Association; 2013 Jul 1 [cited 2014 Aug 14]. Available from: http://www.pharmacist.com/specialty-pharmacy-unique-andgrowing-industry
22. Optum. Symmetry Pharmacy Risk Groups [Internet]. Eden Prairie (MN): Optum; c2014 [cited 2014 Aug 14]. Available from: http://www.optum.com/providers/analytics/health-plan-analytics/symmetry/symmetry-pharmacy-riskgroups. html
23. To access the Appendix, click on the Appendix link in the box to the right of the article online
24. Authors' analysis of information available on the websites of offset card programs of the manufacturers of multiple sclerosis and biologic anti-inflammatory specialty drugs; and NeedyMeds [home page on the Internet]. Gloucester (MA): NeedyMeds; [cited 2014 Aug 14]. Available from: http://needymeds.org
25. Fein AJ. Express Scripts and the inevitability of formulary exclusion. Drug Channels [blog on the Internet]. 2013 Oct 22 [cited 2014 Aug 14]. Available from: http://www.drugchannels.net/2013/10/express-scripts-and-inevitability-of.html
26. Pollack A. Health Insurers pressing down on drug prices. New York Times. 2014 Jun 20.
27. Gavil AI, Gaynor MS, Feinstein D. Contract year 2015 policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs [Internet]. Washington (DC): Federal Trade Commission; 2014 Mar 7 [cited 2014 Aug 14]. Available from: http://www.ftc.gov/system/files/documents/advocacy_ documents/federal-tradecommission-staff-comment-centersmedicare-medicaid-servicesregarding-proposed-rule/140310cmscomment.pdf
28. Brooker C. Waging war on specialty pharmaceutical tiering in pharmacy benefit design. Health Law and Policy Brief. 2013;7(2):25-48.
29. Fronstin P. Self-insured health plans: state variation and recent trends by firm size. Washington (DC): Employee Benefit Research Institute; 2012 Nov [cited 2014 Aug 14]. Available from: http://www.ebri.org/pdf/notespdf/EBRI_Notes_11_Nov-12.Slf-Insrd1.pdf